Company
ASX · ASX:MSB / NASDAQ:MESO
Mesoblast
Longevity exposure
How this company touches longevity
First FDA-approved MSC product (Ryoncil).
Recent inflection
What moved lately
Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD.
Coverage
More on Mesoblast.
Every entity profile on variis is sourced. Not investment advice.